Key Findings from Treatment Algorithms: Multiple Sclerosis

Decision Resources, Inc, December 2011, Pages: 36

Until recently, the MS market comprised a stable mix of time-tested disease-modifying therapies with established roles in treatment—several interferon-beta (IFN-ß) products, glatiramer acetate (Teva’s Copaxone), and natalizumab (Biogen Idec/Elan’s Tysabri). Today, however, the MS market stands at the brink of transformation.

The 2010 launch of fingolimod (Novartis/Mitsubishi Tanabe Pharma’s Gilenya)—the first orally administered disease-modifying drug for MS—marks the beginning of a new era in MS treatment that will feature enhanced treatment choice, increasingly complex decision-making for prescribers, and an invigorated push toward individualized treatment.

In the coming years, neurologists will strive to integrate new therapeutic options with unique risk/benefits into an ingrained treatment paradigm that favors long-term safety and clinical experience—even at the expense of more-robust efficacy.

1. Background
a) Publication Update
b) Report Contents and Features
c) Current Practice Guidelines
d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients
a) Executive Summary
b) Graphical Views

3. Key Findings for Recently Treated Patients
a) Executive Summary
b) Graphical Views

4. Key Findings by Product
a) Copaxone
b) Avonex
c) Rebif
d) Betaseron/Extavia
e) Tysabri
f) Gilenya

5. Appendix: Methodology

Customers who bought this item also bought

• ChartTrends®: Multiple Sclerosis (US) 2011
• Physician and Payer Attitudes Toward Gilenya and Emerging Oral and Parenteral Disease-Modifying Therapies in the U.S. Multiple Sclerosis Market
• ChartTrends®: Multiple Sclerosis (EU) 2011
• Multiple Sclerosis Therapeutics - Global Strategic Business Report
• Thought Leader Insight & Analysis Report - Multiple Sclerosis Q2 2010
• Key Findings from Treatment Algorithms: Crohn's Disease
• DRG Insights: Multiple Sclerosis (G7)
• DRG Insights: Osteoporosis
• Biotech in Autoimmune and Inflammatory Disease 2006, 2nd Edition
• Thought Leader Insight & Analysis Report - Multiple Sclerosis Q3 2011